Former Senior Executive of U.S. Pharmaceutical Company

Represented a former senior executive of a cutting-edge drug and biotechnology company in off-label marketing investigations by the Food and Drug Administration (FDA) and United States Attorneys’ Office.

Firm Highlights

In Unanimous 'Kousisis' Decision, US Supreme Court Widens Scope for Federal Fraud Prosecutions

DOJ Antitrust Division and U.S. Postal Service Partner on New Antitrust Whistleblower Program

Anti-Money Laundering Fines in the U.S. Decline

Which Party Loses Out When Settlement Funds Are Wired to a “Spoofer” and Not Plaintiff?